ArticleNeurosurgical review2025
Subgroup analysis of pipeline Flow-Diverter devices in the treatment of intracranial aneurysms: A long-term real-world study involving 190 patients.
Article in Neurosurgical review, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
The Pipeline is currently the most widely used flow-diverting device worldwide, yet research on its long-term efficacy remains limited, primarily based on small to medium-sized sample cohorts. The objective of this study was to evaluate the long-term safety and efficacy of the Pipeline device in treating intracranial aneurysms. Additionally, the study aimed to analyze the risk factors associated with long-term incomplete occlusion of the aneurysm and stenosis of the parent artery. This multicenter retrospective study included patients with intracranial aneurysms treated with the Pipeline flow-diverting device between 2015 and 2020. The analysis encompassed clinical and imaging outcomes, including clinical presentation, comorbidities, aneurysm characteristics, procedural details, and postoperative follow-up data. This study included 190 patients(122 females)with a mean age of 54.6 ± 11.7 years and 204 aneurysms. At one year postoperatively, the complete aneurysm occlusion rate was 69.9%, parent artery stenosis was 3.7%, and complications occurred in 3.3% of cases. During long-term follow-up, the occlusion rate increased to 93.1%, stenosis rose to 6.4%, and complications decreased to 2.1%. Three perforator occlusions were reported: two during the short-term follow-up and one during the long-term follow-up, resulting in severe impairment (mRS 4). The Pipeline flow-diverting device demonstrated favorable long-term safety and efficacy in the treatment of intracranial aneurysms, with no significant differences in safety or effectiveness between vertebral artery aneurysms and anterior circulation aneurysms. Statistical analysis identified advanced age and male gender as risk factors for long-term incomplete occlusion. Furthermore, the results suggest that postoperative antiplatelet therapy and imaging follow-up were continued for only one year, which is considered safe and effective.
Indexed as
Identifiers
41074981What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.